WO2012070701A1 - 퀴놀린 유도체 화합물, 이의 제조방법 및 이를 포함하는 약학 조성물 - Google Patents
퀴놀린 유도체 화합물, 이의 제조방법 및 이를 포함하는 약학 조성물 Download PDFInfo
- Publication number
- WO2012070701A1 WO2012070701A1 PCT/KR2010/008349 KR2010008349W WO2012070701A1 WO 2012070701 A1 WO2012070701 A1 WO 2012070701A1 KR 2010008349 W KR2010008349 W KR 2010008349W WO 2012070701 A1 WO2012070701 A1 WO 2012070701A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound represented
- pharmaceutically acceptable
- present
- acid
- Prior art date
Links
- IJGRUSBFEIVXQP-UHFFFAOYSA-N C(CNC1Cc2c-3cccc2)c2c1c-3ccc2 Chemical compound C(CNC1Cc2c-3cccc2)c2c1c-3ccc2 IJGRUSBFEIVXQP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
Definitions
- the present invention relates to quinoline derivative compounds, optical isomers thereof, pharmaceutically acceptable salts thereof, hydrates or solvates thereof, methods for their preparation and pharmaceutical compositions comprising the same.
- Pathological mechanisms of functional gastrointestinal disorders may act simultaneously and exhibit one symptom, but mainly occur in a combination of actions. According to symptoms, it is classified into ulcer-like dyspepsia, dysmotility-like dyspepsia, reflux-like dyspepsia, and nonspecific or unspecified functional dyspepsia.
- gastrointestinal diseases The prevalence of functional gastrointestinal diseases is 25-50% worldwide, and about 5% of all medical examinations require patients. In Western countries, the incidence rate is low, such as 22% in the UK and 19% in the US, and varies from region to region with 35-42% in Japan and 62% in East Africa. In Korea, gastrointestinal disease is the second most common disease, especially the incidence of gastrointestinal diseases is high, and 30-40% of the people are experiencing functional gastrointestinal diseases. As described above, functional gastrointestinal diseases are not only high in prevalence but also have severe symptoms, and therefore, patients need to be treated effectively because of poor quality of life and frequent medical treatment.
- a functional gastrointestinal disease whose cause is not obvious is defined as a functional symptom rather than histopathological and biochemical organic lesions, and treatment is being performed in a direction of reducing the symptoms.
- Many symptoms of functional gastrointestinal disorders can be treated, primarily by promoting gastrointestinal motility.
- Functional dyspepsia one of the representative gastrointestinal motility disorders, is diagnosed by various various indigestion symptoms without any obvious organic lesions. Therefore, treatment is not simple and most symptoms are repeated and improved. The change is severe. These pathological mechanisms may work simultaneously and produce one symptom, but they usually occur in a combination of actions. Specifically, functional dyspepsia includes all digestive symptoms such as satiety, anorexia, abdominal bloating, premature satiety, belching, upper abdominal discomfort or pain, heartburn, nausea (nausea), vomiting, stomach acid reflux, and heartburn. And pathophysiology is not yet fully understood (Panganamamula et. Al., Functional (Nonulcer) Dyspepsia, Current Treatnett Optionsin Gastroenterology, 5, pp. 153-160, 2002).
- Representative functional dyspepsia agents include gastrointestinal motility promoters such as domperidone, metoclopramide, levosulpiride, mosapride, itopride, and erythromycin. And other drugs.
- gastric acid secretion inhibitors and antacids are used because the typical symptoms of functional dyspepsia are heartburn and ulcers, but gastric acid secretion inhibitors and antacids, including H2 antagonists, often have a temporary effect (Vincenzo Stanghellini et al., Delayed). Gastric Emptying in Functional Dyspepsia, Current Treatment Options in Gastroenterology, 7, 259-264, 2004).
- the 5-HT4 receptor agonist one of the recently used prokinetic drugs for the treatment of functional dyspepsia, improves symptoms without increasing tension at the bottom of the crisis.
- Cisapride one of the 5-HT4 receptor agonists, has a gastric fasting effect and a statistically significant effect compared to other drugs, but in association with the duodenum or intragastric pressure wavelength (> 6 cm), only patients It also raises the threshold for cognitive bloating in healthy people and can also have fatal side effects.
- the existing gastrointestinal motility regulators other than cisapride the effect is far less than that of cisapride, it is necessary to develop a stable and effective functional indigestion or gastrointestinal motility disorders treatment without side effects.
- the present invention provides novel quinoline derivative compounds, their optical isomers, their pharmaceutically acceptable salts and their hydrates or solvates.
- the present invention provides novel quinoline derivative compounds, their optical isomers, their pharmaceutically acceptable salts and their hydrates or solvates.
- the present invention provides a pharmaceutical composition for the prevention or treatment of diseases of the gastrointestinal motility disorders, including the novel quinoline derivative compounds, optical isomers thereof, pharmaceutically acceptable salts thereof, hydrates or solvates thereof.
- the present invention provides the use of the novel quinoline derivative compounds, their optical isomers, their pharmaceutically acceptable salts, their hydrates or solvates, for the prevention or treatment of diseases of the gastrointestinal motility disorders.
- the present invention provides a method for preventing or treating gastrointestinal motility disorder disease using quinoline derivative compounds, optical isomers thereof, pharmaceutically acceptable salts thereof and hydrates or solvates thereof.
- the present invention provides a quinoline derivative compound represented by Formula 1 below, an optical isomer thereof, a pharmaceutically acceptable salt thereof, and a hydrate or solvate thereof.
- R 1 to R 4 are independently -H; Or methoxy,
- R 5 is C1 to C4 straight or branched alkyl.
- the compound represented by Chemical Formula 1 of the present invention may include an asymmetric carbon.
- the present invention may include not only the compound represented by Chemical Formula 1 but also all optical isomers thereof.
- the quinoline derivative compound represented by Formula 1 may be a compound represented by Formula 2 below.
- * represents an asymmetric carbon
- the present invention may include all of the compounds represented by Formula 2, optical isomers thereof, pharmaceutically acceptable salts thereof, hydrates or solvates thereof.
- the present invention includes the following compounds, their optical isomers, their pharmaceutically acceptable salts, their hydrates or solvates.
- the pharmaceutically acceptable salts refer to salts commonly used in the pharmaceutical industry, for example, inorganic ions, hydrochloric acid, nitric acid, phosphoric acid, bromine, and the like prepared from calcium, potassium, sodium, magnesium, and the like.
- Inorganic acid salts prepared with acids, iodic acid, perchloric acid, tartaric acid and sulfuric acid, acetic acid, trifluoroacetic acid, citric acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, manderic acid, propionic acid, citric acid, lactic acid, glycolic acid , Gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorbic acid, carbonic acid, vanic acid, hydroiodic acid, mandelic acid, munic acid, nitric acid, pamoic acid, pantothenic acid, succinic acid, tartaric acid Sulfonic acid salts prepared with organic acid salts, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, or
- Hydrates of compounds represented by Formula 1 or 2, compounds listed above, optical isomers thereof, or pharmaceutically acceptable salts thereof of the present invention may contain stoichiometric or non-stoichiometric amounts of water bound by non-covalent intermolecular forces. It may include.
- the hydrate may contain at least one equivalent, that is, from one equivalent to five equivalents of water.
- Such hydrates can be prepared by crystallizing the compound represented by Formula 1 or 2, optical isomers thereof or pharmaceutically acceptable salts thereof of the present invention from water or a solvent containing water.
- the stoichiometric or non-stoichiometric amounts of the compounds represented by Formula 1 or 2 of the present invention, the compounds listed above, the optical isomers thereof or pharmaceutically acceptable salts thereof are bound by non-covalent intermolecular forces. It may include a solvent of. Preferred solvents include those which are non-volatile, non-toxic or suitable for administration to humans, for example ethanol, methanol, propanol, methylene chloride and the like.
- the compounds represented by Formula 1 or 2 of the present invention may prevent or treat gastrointestinal motility disorder diseases.
- the compounds of the present invention are compounds represented by Formula 1 or 2, the compounds listed above, their optical isomers, their pharmaceutically acceptable salts, their hydrates or solvates are dopamine-D2 receptors, serotonin-1A. It has affinity for receptors and serotonin-1B receptors, and its action with the receptors can effectively prevent or treat various symptoms and disorders in gastrointestinal motility disorders.
- the present invention provides a compound represented by the following formula (1) comprising reacting a compound represented by the following formula (3) or an optical isomer thereof with a compound represented by the following formula (4) or an optical isomer thereof in the presence of a base, an optical isomer thereof, Provided are methods of preparing their pharmaceutically acceptable salts, hydrates or solvates thereof.
- R 1 to R 4 are independently -H; Or methoxy,
- R 5 is C1 to C4 straight or branched alkyl
- X is Cl, Br or I
- the compound represented by Chemical Formula 3 or an optical isomer thereof may be prepared by a known method, or may be purchased and used commercially.
- the compounds can be obtained from known extracts of Corydalis tuber (Tae Ho Lee et al., Biol. Pharm. Bull. 33 (6) 958-962 (2010), “Effects of Corydaline from Corydalis Tuber). on Gastric Motor Function in an Animal Model ", Ki Hyun Kim et al., Planta Med. 2010 May 27,” New Cytotoxic Tetrahydroprotoberberine-Aporphine Dimeric and Aporphine Alkaloids from Corydalis Turtschaninovii ".
- the compound represented by Chemical Formula 3 is represented by Chemical Formula 2, wherein 1,2,9,10-tetramethoxy-5,6,6a, 7-tetrahydro-4H -Dibenzo [de, g] quinoline ((+)-norglausin), the compound represented by the formula (4) is ethyl 4-chloro-4-oxobutanoate (ethyl 4-chloro-4-oxobutanoate May be).
- the preparation method of the present invention may include a reaction represented by Scheme 1 below.
- R 1 to R 4 are independently -H; Or methoxy,
- R 5 is C1 to C4 straight or branched alkyl
- X is Cl, Br or I
- R 1 to R 4 may be methoxy
- R 5 may be ethyl
- X may be Cl
- the optical purity of the compound represented by Formula 1 may be determined by the optical purity of the compound represented by Formula 3. Therefore, when using the pure optical isomer of the compound represented by the formula (3), specific optical isomers of the compound represented by the formula (1) can be obtained. For example, when the optical isomer of the compound represented by the formula (3) having the optical stereostructure of (S) is used, the optical isomer of the compound represented by the formula (1) having the optical stereostructure of (S) can be obtained. .
- the racemic compound represented by the formula (1) when using the racemic compound represented by the formula (3), the racemic compound represented by the formula (1) can be obtained, in this case, to obtain a compound having a desired optical three-dimensional structure by a known method to obtain Can be.
- the reaction represented by Scheme 1 may be performed in an organic solvent.
- the type of the organic solvent is not particularly limited, for example, methanol, ethanol, propanol, dimethyl sulfoxide (DMSO), tetrahydrofuran (THF), acetonitrile (ACN), dimethylformamide (DMF), N -Methylpyrrolidinone (NMP), dimethylacetamide (DMA) or mixtures thereof and the like can be used.
- the reaction represented by Scheme 1 may be performed in the presence of a base.
- the base may be appropriately selected from a variety of bases, for example, triethylamine, N, N-diisopropylethylamine, N-methylporporin, N-methylpiperidine, 4-dimethylaminopyridine, N, N-dimethylaniline, 2, 6-lutidine, potassium triphosphate, potassium carbonate, pyridine or mixtures thereof can be used, preferably triethylamine can be used.
- the present invention provides a pharmaceutical composition for preventing or treating a gastrointestinal motility disorder disease, which comprises a quinoline derivative compound represented by Formula 1 below, an optical isomer thereof, a pharmaceutically acceptable salt thereof, and a hydrate or solvate thereof.
- R 1 to R 4 are independently -H; Or methoxy,
- R 5 is C1 to C4 straight or branched alkyl.
- the pharmaceutical composition of the present invention may include a compound represented by Formula 2 below, an optical isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof.
- * represents an asymmetric carbon
- the pharmaceutical composition of the present invention may include the following compounds, optical isomers thereof, pharmaceutically acceptable salts thereof, hydrates or solvates thereof.
- the pharmaceutically acceptable salts, hydrates and solvates in the pharmaceutical composition are substantially the same as described above.
- the pharmaceutical composition of the present invention can be used to prevent or treat functional gastrointestinal disorders such as gastrointestinal motility disorders.
- the gastrointestinal motility disorder diseases include premature satiety, pain, epigastric discomfort, flatulence, heartburn, nausea, vomiting, functional dyspepsia, ulcer dyspepsia, non-ulcer dyspepsia, gastro-esophageal reflux disease, reflux esophagitis, gastrointestinal disorder , False bowel obstruction, gastric palsy, constipation, irritable colitis, general irritable colitis, irritable colitis with constipation, irritable colitis with diarrhea, diabetic gastrointestinal dyskinesia, gastrointestinal dyskinesia due to chemotherapy, digestive tract dyskinesia Due to intestinal obstruction, myotonic dystrophy, gastrointestinal motility disorder and non-cardiac chest pain.
- the functional dyspepsia is a functional symptom that is not a histopathological and biochemical organic lesion, but a symptom of persistent discomfort or pain in the upper abdomen, and is limited to the upper abdomen medically and repeatedly. Means all the symptoms associated with discomfort or pain.
- functional indigestion includes gastrointestinal symptoms such as satiety, poor food, abdominal bloating, premature satiety, belching, upper abdominal discomfort or pain, heartburn, nausea (nausea), vomiting, gastric acid reflux, and heart burn. do.
- gastrointestinal dyskinesia such as delayed gastric emptying time for food to pass through the pyloric stomach to the small intestine.
- the stomach is properly stretched to maintain gastrointestinal pressure.
- the pharmaceutical composition of the present invention can improve gastric emptying capacity, gastric compliance and gastrointestinal metastasis of food, and can also activate gastrointestinal motility. Thus, various symptoms in functional dyspepsia or gastrointestinal dyskinesia can be effectively prevented or treated.
- the pharmaceutical composition of the present invention may improve gastric emptying ability, gastric compliance and gastrointestinal tract metastasis without adverse effects such as causing adverse effects on the heart, and may also improve gastrointestinal motility.
- the pharmaceutical composition of the present invention has an affinity for the dopamine-D2 receptor, serotonin-1A receptor and serotonin-1B receptor, and effectively prevents various symptoms and diseases in gastrointestinal motility disorders through their interaction with the receptors. It can be cured.
- the pharmaceutical composition of the present invention has a high affinity for the dopamine-D2 receptor.
- Dopamine-D2 receptors are receptors found in many mammalian gut walls and are known to inhibit gastrointestinal motility. Domperidone and metoclopramide, which are selective antagonists of the inhibitory dopamine-D2 receptor, exhibit gastrointestinal motility effects.
- antagonists of dopamine-D2 receptors inhibit vomiting, such as levosulfide, clevoprid and bromoprid, which are used in some countries as antiemetic agents along with gastrointestinal motility effects (P. Moayyedi, S. Soo). , J. Deeks, B. Delaney, M. Innes and D.
- the pharmaceutical composition of the present invention having a high affinity for the dopamine-D2 receptor may act as an antagonist of the dopamine-D2 receptor like the drug to promote gastrointestinal motility.
- the pharmaceutical composition of the present invention exhibits high affinity for the serotonin-1A receptor.
- Serotonin-1A receptors play a role in regulating gastric compliance
- Bushpyron an agonist of serotonin-1A receptors
- R-137696 a serotonin-1A agonist under development, relaxed the gastric proximal part in a dose-dependent study (GE Boeckxstaens, GN Tytgat, E. Wajs, L. van Nueten, F. de Ridder, A. Meulemans and J.
- the pharmaceutical composition of the present invention which has an affinity for the serotonin-1A receptor, may also exhibit an effect of improving gastric compliance.
- compositions of the present invention also exhibit high affinity for serotonin-1B receptors.
- Sumatriptan an agonist for serotonin-1B receptors, has a gastrointestinal relaxation effect and also reduces gastrointestinal dysfunction in dysfunctional patients (Tack, H. Piessevaux, B. Coulie, P. Caenepeel and J). Janssens, Role of impaired gastric accommodations to a meal in functional dyspepsia, Gastroenterology 115 (1998), pp. 1346-1352; J. Tack, P. Vanden Berghe, B. Coulieand J.
- the pharmaceutical composition of the present invention which exhibits high affinity for serotonin-1B receptor, may also exhibit an effect of preventing or treating gastric compliance disorder by reducing gastrointestinal relaxation effect and dietary satiety.
- the pharmaceutical composition of the present invention may include at least one compound represented by Chemical Formula 1 or 2, the compounds listed above, optical isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof, or solvates thereof. Can be.
- the pharmaceutical composition may include one compound represented by Formula 1 or 2, the compounds listed above, optical isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof, or solvates thereof. Or two or more.
- the pharmaceutical composition of the present invention is in addition to the compound represented by the formula (1) or (2), the compounds listed above, optical isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof or solvates thereof. It may further comprise an active ingredient having a prophylactic or therapeutic effect against a kind of gastrointestinal motility disorder disease.
- the pharmaceutical composition may further include domperidone, metoclopramide, metoclopramide, levosulpiride, mosapride, itopride, and erythromycin. Can be.
- the pharmaceutical composition of the present invention may further include other pharmaceutically active ingredients that are effective for diseases other than the indigestion or gastrointestinal motility disorders.
- composition of the present invention may be used alone or in combination with methods using surgery, hormonal therapy, drug treatment or biological response modifiers to prevent or treat gastrointestinal motility disorders.
- the pharmaceutical composition of the present invention in addition to the compound represented by the formula (1) or (2), the enumerated compounds, optical isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof or solvates thereof for administration. It may further comprise one or more pharmaceutically acceptable carriers.
- the pharmaceutically acceptable carrier may be used in combination with saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol and one or more of these components, if necessary, antioxidants, Other conventional additives such as buffers and bacteriostatic agents can be added.
- the pharmaceutical composition of the present invention can be administered orally or parenterally (eg, applied intravenously, subcutaneously, intraperitoneally or topically) according to the desired method, and the dosage is based on the weight, age, sex and health of the patient.
- the range varies depending on the diet, the time of administration, the method of administration, the duration or interval of administration, the rate of excretion, constitution specificity, the nature of the formulation, and the severity of the disease.
- the daily dosage of the compound represented by Formula 1 of the present invention, optical isomer thereof, pharmaceutically acceptable salt thereof, hydrate thereof or solvate thereof is about 0.01 to 100 mg / kg, preferably 0.1 to It is 30 mg / kg, and it is more preferable to divide and administer once to three times a day.
- the pharmaceutical composition of the present invention may be formulated in various preparations for administration.
- the pharmaceutical compositions can be formulated in various forms with the addition of excipients.
- the excipients are nontoxic and inert pharmaceutically suitable solid, semisolid or liquid formulation aids of all types, for example fillers, weights, binders, wetting agents, disintegrants, dispersants, surfactants or diluents and the like. Can be mentioned.
- the pharmaceutical composition of the present invention may be formulated in dosage unit form.
- the content per formulation of the compound represented by Formula 1 or 2, the compounds listed above, the optical isomers thereof, the pharmaceutically acceptable salts thereof, the hydrates or solvates thereof, per dosage form may be Corresponds to the fraction or multiple.
- the formulated dosage unit may comprise 1, 2, 3 or 4 times, or 1/2, 1/3 or 1/4 times the daily individual dosage of the active compound.
- Preferably said individual dose contains an amount in which the active compound is administered at one time, which usually corresponds to all, 1/2, 1/3 or 1/4 times the daily dose.
- the pharmaceutical composition of the present invention is formulated into tablets, coated tablets, capsules, pills, granules, suppositories, solutions, suspensions and emulsions, pastes, ointments, gels, creams, lotions, powders or sprays. Can be converted.
- the pharmaceutical composition may be formulated as a solid preparation such as tablets, pills, powders, granules or capsules or liquid preparations such as suspensions, solvents, emulsions or syrups for oral administration.
- the pharmaceutical composition may be formulated as an injection, suspension, emulsion, lyophilized or suppository for parenteral administration.
- the pharmaceutical composition may be formulated in a microcapsule form using a compound represented by Chemical Formula 1, an optical isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof, and one or more excipients. Can be converted.
- compositions of the present invention When the pharmaceutical composition of the present invention is formulated into solid preparations such as tablets, coated tablets, capsules, pills or granules, (a) fillers such as starch, lactose, sucrose, glucose, mannitol or silicic acid And a weight agent, (b) a binder such as carboxymethyl cellulose, alginate, gelatin, polyethylene glycol, microcrystalline cellulose, highly dispersible silica, natural gum, synthetic gum, povidone, copovidone, polyvinylpyrrolidone or gelatin, (c) hygroscopic agents such as glycerol, (d) disintegrants such as agar, calcium carbonate or sodium carbonate, (e) dissolution retardants such as paraffin, (f) absorption accelerators such as quaternary ammonium compounds, (g) cetyl alcohol or Wetting agents such as glycerol monostearate, (h) adsorbents such as kaolin or bentonite,
- the pharmaceutical composition is formulated as a liquid preparation such as an oral suspension, an aqueous solution, an emulsion or a syrup, a simple diluent such as water and liquid paraffin, a wetting agent, a sweetening agent, a fragrance, a preservative, a preservative, and a coloring agent. It may be formulated by the addition of various additives such as.
- the pharmaceutical composition may be formulated by further adding a sweetener such as peppermint oil, eucalyptus oil or saccharin.
- fats such as polyethylene glycol, cacao fat, higher esters (e.g., C14-alcohols with C16-fatty acid), witepsol, macrogol, tween 61, can be formulated using water-soluble or insoluble excipients such as laurin paper and glycerol gelatin or mixtures thereof.
- composition of the present invention is formulated as an ointment, paste, cream or gel, animal and vegetable fats, wax paraffin, starch, targacanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silicic acid, talc, It can be formulated using zinc oxide or mixtures thereof.
- the pharmaceutical composition of the present invention when formulated as a powder or a spray, it may be formulated using lactose, talc, silicic acid, aluminum hydroxide, calcium silicate, polyamide powder or mixtures thereof.
- a conventional fossa such as chlorofluorohydrocarbon may be further used, and may also be formulated as a nasal spray using Fiji-4000 and glycerin.
- the pharmaceutical composition of the present invention when formulated as a parenteral solution or emulsion, it may be formulated using a solvent, a solubilizer or an emulsifier.
- the composition of the present invention may include water, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, cottonseed oil, peanut oil, Oils such as corn seed oil, olive oil, castor oil or sesame oil oil, glycerol, glycerol form alcohol, tetrahydrofurfuryl alcohol, polyethylene glycol, fatty acid esters of sorbitan or mixtures thereof can be formulated as liquids or emulsions. have.
- the parenteral solution or emulsion may be formulated in sterile form isotonic with blood.
- liquid diluents such as polyethylene glycol, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum It may be formulated using injectable esters such as metahydroxy, bentonite, agar, tragacanth, ethyl oleate, mixtures thereof.
- compositions according to the invention can be formulated in sustained or immediate release formulations using carriers, diluents, dispersants, surfactants, binders, lubricants and additives.
- the pharmaceutical composition according to the present invention is a compound represented by the formula (1) or (2), the above-listed compounds, their optical isomers, their pharmaceutically acceptable salts, their hydrates or their It may be formulated in a sustained or immediate release formulation to release the solvate.
- the pharmaceutical composition according to the present invention when formulated into a sustained release formulation, it may be formulated in a sustained release form using a sealing agent composition such as a wax or a polymerizable material such as an enteric polymer, a water insoluble polymer, a hydrophobic compound or a hydrophilic polymer.
- a sealing agent composition such as a wax or a polymerizable material such as an enteric polymer, a water insoluble polymer, a hydrophobic compound or a hydrophilic polymer.
- a sealing agent composition such as a wax or a polymerizable material such as an enteric polymer, a water insoluble polymer, a hydrophobic compound or a hydrophilic polymer.
- the content of excipients and additives such as carriers, fillers, weighting agents, binders, wetting agents, disintegrants, dispersants, surfactants or diluents to be added is not particularly limited, and conventional formulations It may be appropriately adjusted within the content range used for the sake.
- compositions of the present invention may be formulated in a suitable manner for each disease or ingredient using appropriate methods in the art.
- the compound represented by Chemical Formula 1 or 2 the compounds listed above, optical isomers thereof, or pharmaceutically acceptable salts and excipients thereof may be mixed and formulated into a desired formulation.
- the pharmaceutical composition of the present invention is a compound represented by the formula (1) or (2), the compounds listed above, optical isomers thereof, pharmaceutically acceptable salts thereof, hydrates or solvates thereof in the whole composition About 0.1 to about 99.5% by weight, preferably about 0.5% to about 95% by weight.
- the present invention is a gastrointestinal motility disorder of a pharmaceutical composition
- a pharmaceutical composition comprising a compound represented by the formula (1) or (2), the compounds listed above, optical isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof or solvates thereof It provides a prophylactic or therapeutic use for disease.
- the present invention is digested using a pharmaceutical composition
- a pharmaceutical composition comprising a compound represented by Formula 1 or 2, the compounds listed above, optical isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof, or solvates thereof
- the pharmaceutical composition may be administered to a subject including a mammal to prevent or treat dyspepsia or gastrointestinal motility disorder disease.
- novel quinoline derivative compounds of the present invention can activate gastrointestinal motility. Therefore, the composition comprising the quinoline derivative compounds of the present invention, optical isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof or solvates thereof effectively prevents various symptoms in functional dyspepsia or gastrointestinal motility disorders. Or can be treated.
- (+)-Norglasin is known from extracts of Corydalis tuber (Tae Ho Lee et al., Biol. Pharm. Bull. 33 (6) 958-962 (2010), "Effects of Corydaline from Corydalis Tuber on Gastric Motor Function in an Animal Model ", Ki Hyun Kim et al., Planta Med. 2010 May 27,” New Cytotoxic Tetrahydroprotoberberine-Aporphine Dimeric and Aporphine Alkaloides from Corydalis Turtschaninovii ".
- 1 H-NMR data is measured by Varian's UNITY INOVA 500 NMR spectrometer, IR data is Bruker's IFS-66 / S FT-IR spectrometer, UV data is Shimadzu's UV-1601 UV-visible spectrophotometer and CD data Measured by JASCO's J-715 spectropolarimeter. Mass data was measured by JEOL's JMS700 mass spectrometer.
- the binding receptor was isolated by filtration using Whatman GF / B, unifilter-96, Lot: 6005177, PerkinElmer. The bound receptor of the isolated type was washed three times with Tris-HCl buffer. After that, 10 mL of scintillation cocktail (Slottillation cocktail, Lot: 03999, Fluka) was added and reacted for at least 16 hours, and then a beta-counter (pakcard) was used to calculate the amount of tritium piperone bound to the receptor. The radiation dose was measured. In order to calculate the nonspecific binding value, the value measured by adding 10 ⁇ M of haloperidol (haloperidol, H1512, Sigma) to 0.16 nM tritium piperone was used. The experiment was repeated twice, and receptor affinity was calculated using Equation 1 below, and the average is shown in Table 1 below.
- % Receptor affinity ⁇ (total CPM-nonspecific binding CPM-CPM with tritiumsphyfferon remaining after addition of compounds of the invention) / (total CPM-nonspecific binding CPM) ⁇ ⁇ 100
- the compounds of the present invention showed a high affinity for the dopamine-D2 receptor at a concentration of 10 ⁇ M. From this, it can be seen that the compounds of the present invention can promote gastrointestinal motility, such as domperidone, metoclopramide, or itopride, which act as an antagonist to the dopamine-D2 receptor.
- gastrointestinal motility such as domperidone, metoclopramide, or itopride
- CHO cells transfected with human dopamine 5-HT1A receptors were treated with Tris-HCl (50 mM Tris-HCl, pH 7.4, 120 mM NaCl, 5 mM KCl, 2 mM CaCl 2 , 1). incubated with 1.5 nM [3H] 8-OH-DPAT and 10 ⁇ M of the compound of Example for 1 hour and 30 minutes in mM MgCl 2 ). After incubation, the binding receptor was isolated by filtration with Whatman GF / B, unifilter-96, Lot: 6005177, PerkinElmer. The isolated receptor of the bound type was washed three times with 5 mL of Tris-HCl buffer. Thereafter, 10 mL of scintillation cocktail (Lot: 03999, Fluka) was added and reacted for at least 16 hours, and then a beta-counter (beta-counter, The radiation dose was measured using pakcard).
- Tris-HCl 50 mM Tris-HCl
- % Receptor affinity ⁇ (total CPM-nonspecific binding CPM-CPM with remaining [3H] 8-OH-DPAT following addition of compounds of the invention) / (total CPM-nonspecific binding CPM) ⁇ ⁇ 100
- the compounds of the present invention showed a certain affinity for the serotonin 1-A receptor at a concentration of 10 ⁇ M. From this, it can be seen that the compounds of the present invention can bind to serotonin 1-A and improve gastric compliance.
- the binding receptor was isolated by filtration using Whatman GF / B, unifilter-96, Lot: 6005177, PerkinElmer.
- the isolated receptor of the bound type was washed three times with 5 mL of Tris-HCl buffer. After that, 10 mL of scintillation cocktail (Lot: 03999, Fluka) was added and reacted for at least 16 hours, and then beta-counter (pakcard) to calculate the amount of iodine 125 cyanopindolol bound to the receptor.
- the radiation dose was measured using.
- % Receptor affinity ⁇ (total CPM-nonspecific binding CPM-CPM with remaining iodine 125 cyanopindolol following addition of compounds of the invention) / (total CPM-nonspecific binding CPM) ⁇ ⁇ 100
- the compounds of the present invention showed a high affinity for serotonin-1B at a concentration of 10 ⁇ M. From this, it can be seen that the compounds of the present invention bind to serotonin-1B, exhibit gastrointestinal relaxation effects, and alleviate gastric compliance disorders.
- the animal feed was put in water and pulverized and semi-solid type (semisolidal teast meal, 0.05% phenol red solution containing 1.5% MC) was orally administered 2mL per horse.
- semi-solid type semisolidal teast meal, 0.05% phenol red solution containing 1.5% MC
- the stomach was removed at the expense of the SD rats, and the weight of the stomach was measured so that the contents of the stomach did not fall out.Then, the stomach was washed with distilled water, the contents remaining inside the stomach were removed and dried.
- the weight of the semisolid food remaining above was calculated by measuring the weight of.
- the above discharge rate was calculated according to the following Equation 4, the results are shown in Table 4.
- the control group was orally administered only 1 mL of 3% hydroxymethylcellulose.
- novel quinoline derivative compounds of the present invention can activate gastrointestinal motility. Therefore, the composition comprising the quinoline derivative compounds of the present invention, optical isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof or solvates thereof effectively prevents various symptoms in functional dyspepsia or gastrointestinal motility disorders. Or can be treated.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
Description
Claims (7)
- 제1항에 있어서, 상기 화학식 1로 표시되는 퀴놀린 유도체 화합물이 (S)-4-옥소-4-(1,2,9,10-테트라메톡시-4,5,6a,7-테트라히드로-디벤조[de,g]퀴놀린-6-일)-부티르산 에틸 에스터((S)-4-oxo-4-(1,2,9,10-tetramethoxy-4,5,6a,7-tetrahydro-dibenzo[de,g]quinoline-6-yl)-butyric acid ethyl ester)인 것인 퀴놀린 유도체 화합물, 이의 광학이성질체, 이들의 약제학적으로 허용 가능한 염, 이들의 수화물 또는 용매화물.
- 염기 존재 하에서 하기 화학식 3으로 표시되는 화합물 또는 이의 광학 이성질체를 하기 화학식 4로 표시되는 화합물과 반응시키는 단계를 포함하는 하기 화학식 1로 표시되는 화합물, 이의 광학 이성질체, 이들의 약제학적으로 허용 가능한 염, 이들의 수화물 또는 용매화물을 제조하는 방법.상기 화학식 1, 3 및 4에서,상기 R1 내지 R4은 독립적으로 -H; 또는 메톡시이며,R5는 C1 내지 C4의 직쇄 또는 분지쇄의 알킬이며,X는 Cl, Br 또는 I이며,*는 비대칭 탄소를 나타낸다.
- 제4항에 있어서, 상기 화학식 1, 3 및 4에서 상기 R1 내지 R4는 메톡시이며, 상기 R5는 에틸이고, 상기 X는 Cl인 것인 화학식 1로 표시되는 화합물, 이의 광학 이성질체, 이들의 약제학적으로 허용 가능한 염, 이들의 수화물 또는 용매화물을 제조하는 방법.
- 제6항에 있어서, 상기 화학식 1로 표시되는 퀴놀린 유도체 화합물이 (S)-4-옥소-4-(1,2,9,10-테트라메톡시-4,5,6a,7-테트라히드로-디벤조[de,g]퀴놀린-6-일)-부티르산 에틸 에스터((S)-4-oxo-4-(1,2,9,10-tetramethoxy-4,5,6a,7-tetrahydro-dibenzo[de,g]quinoline-6-yl)-butyric acid ethyl ester)인 것인 약학 조성물.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013540871A JP5599519B2 (ja) | 2010-11-24 | 2010-11-24 | キノリン誘導体化合物、その製造方法およびそれを含む薬学組成物 |
SG2013041231A SG190914A1 (en) | 2010-11-24 | 2010-11-24 | Quinoline derivative compound, method for preparing same, and pharmaceutical composition containing same |
PCT/KR2010/008349 WO2012070701A1 (ko) | 2010-11-24 | 2010-11-24 | 퀴놀린 유도체 화합물, 이의 제조방법 및 이를 포함하는 약학 조성물 |
US13/989,407 US20140155609A9 (en) | 2010-11-24 | 2010-11-24 | Quinoline derivative compound, method for preparing same, and pharmaceutical composition containing same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2010/008349 WO2012070701A1 (ko) | 2010-11-24 | 2010-11-24 | 퀴놀린 유도체 화합물, 이의 제조방법 및 이를 포함하는 약학 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012070701A1 true WO2012070701A1 (ko) | 2012-05-31 |
Family
ID=46146029
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2010/008349 WO2012070701A1 (ko) | 2010-11-24 | 2010-11-24 | 퀴놀린 유도체 화합물, 이의 제조방법 및 이를 포함하는 약학 조성물 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20140155609A9 (ko) |
JP (1) | JP5599519B2 (ko) |
SG (1) | SG190914A1 (ko) |
WO (1) | WO2012070701A1 (ko) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101180174B1 (ko) | 2010-04-23 | 2012-09-05 | 동아제약주식회사 | 신규한 벤즈아미드 유도체 |
KR101341692B1 (ko) | 2011-03-16 | 2013-12-20 | 동아에스티 주식회사 | 복합생약추출물을 함유하는 당뇨병성 말초 신경병증의 치료 및 예방을 위한 조성물 |
KR101341693B1 (ko) | 2011-03-16 | 2013-12-16 | 동아에스티 주식회사 | 생약추출물을 함유하는 퇴행성 신경질환의 치료 및 예방을 위한 조성물 |
KR101457789B1 (ko) | 2013-02-13 | 2014-11-03 | 동아제약 주식회사 | 상처 치료용 필름형성 약제학적 조성물 및 그의 제조방법 |
ES2897946T3 (es) | 2013-07-25 | 2022-03-03 | Dong A St Co Ltd | Método para preparar un derivado de benzamida, intermedio novedoso utilizado en la preparación de la benzamida y método para preparar un intermedio novedoso |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002016325A1 (en) * | 2000-08-23 | 2002-02-28 | Mingjai Su | Uses of thaliporphine or its derivatives in treatment of cardiac diseases and preparation of same |
US20060211723A1 (en) * | 2003-04-04 | 2006-09-21 | Lotus Pharmaceutical Co., Ltd. | Aporphine and oxoaporphine compounds and pharmaceutical use thereof |
WO2007134485A1 (en) * | 2006-05-22 | 2007-11-29 | Lotus Pharmaceutical Co., Ltd. | Aporphine and oxoaporphine compounds and pharmaceutical use thereof |
US20090318488A1 (en) * | 2008-06-20 | 2009-12-24 | Standard Chem. & Pharm. Co., Ltd. | Pharmaceutically acceprable salts of aporphine compounds of carboxyl group-containing agents and methods for preparing the same |
-
2010
- 2010-11-24 SG SG2013041231A patent/SG190914A1/en unknown
- 2010-11-24 JP JP2013540871A patent/JP5599519B2/ja not_active Expired - Fee Related
- 2010-11-24 WO PCT/KR2010/008349 patent/WO2012070701A1/ko active Application Filing
- 2010-11-24 US US13/989,407 patent/US20140155609A9/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002016325A1 (en) * | 2000-08-23 | 2002-02-28 | Mingjai Su | Uses of thaliporphine or its derivatives in treatment of cardiac diseases and preparation of same |
US20060211723A1 (en) * | 2003-04-04 | 2006-09-21 | Lotus Pharmaceutical Co., Ltd. | Aporphine and oxoaporphine compounds and pharmaceutical use thereof |
WO2007134485A1 (en) * | 2006-05-22 | 2007-11-29 | Lotus Pharmaceutical Co., Ltd. | Aporphine and oxoaporphine compounds and pharmaceutical use thereof |
US20090318488A1 (en) * | 2008-06-20 | 2009-12-24 | Standard Chem. & Pharm. Co., Ltd. | Pharmaceutically acceprable salts of aporphine compounds of carboxyl group-containing agents and methods for preparing the same |
Also Published As
Publication number | Publication date |
---|---|
US20130296571A1 (en) | 2013-11-07 |
US20140155609A9 (en) | 2014-06-05 |
JP5599519B2 (ja) | 2014-10-01 |
JP2013543888A (ja) | 2013-12-09 |
SG190914A1 (en) | 2013-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012070701A1 (ko) | 퀴놀린 유도체 화합물, 이의 제조방법 및 이를 포함하는 약학 조성물 | |
KR20020020817A (ko) | 화합물 | |
WO2012138147A2 (en) | 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid crystalline form and the producing method thereof | |
RU2125569C1 (ru) | Производные полизамещенных 2-амидо-4-фенилтиазолов, способ их получения, промежуточные соединения синтеза и фармацевтическая композиция на их основе | |
WO2018056697A1 (ko) | 벤즈이미다졸 유도체의 산부가염 | |
WO2012091440A2 (en) | Composition for improvement, treatment and prevention of gastrointestinal motility disorders | |
WO2012070700A1 (ko) | 퀴놀린 유도체 화합물, 이의 제조방법 및 이를 포함하는 약학 조성물 | |
WO2020231146A1 (ko) | 펠루비프로펜의 신규 염, 이의 제조방법 및 이를 포함하는 약학적 조성물 | |
US5817654A (en) | N-substituted naphthofused lactams | |
WO2016080796A2 (ko) | 세스퀴테르펜 화합물을 포함하는, stat3 매개 질환의 예방 또는 치료용 약학적 조성물 및 이의 용도 | |
WO2019190137A1 (ko) | 1,2-디아실글리세롤 화합물, 그 제조방법 및 이를 유효성분으로 함유하는 면역조절제 | |
SK141997A3 (en) | Derivatives of 10,13,15-trioxatricyclo £9.2.1.1.9.6|pentadecane, method for the preparation thereof and drugs containing such compounds | |
KR101155753B1 (ko) | 퀴놀린 유도체 화합물을 포함하는 약학 조성물 | |
EA003327B1 (ru) | Антивирусные соединения | |
KR101079927B1 (ko) | 퀴놀린 유도체 화합물, 이의 제조방법 및 이를 포함하는 약학 조성물 | |
WO2021112620A9 (ko) | 근감소증 또는 근위축증의 예방 또는 치료용 약제학적 조성물 | |
KR100584017B1 (ko) | 11-아세틸-12,13-디옥사바이시클로〔8.2.1〕-트리데케논 유도체,이의 제조방법 및 이 화합물을 포함하는 약제 | |
KR101086961B1 (ko) | 퀴놀린 유도체 화합물, 이의 제조방법 및 이를 포함하는 약학 조성물 | |
WO2012043900A1 (ko) | 퀴놀린 유도체 화합물을 포함하는 약학 조성물 | |
WO2020040326A1 (ko) | 페닐아세트산 유도체 및 이를 유효성분으로 함유하는 자가면역질환 예방 또는 치료용 조성물 | |
WO2017091041A1 (ko) | 피마살탄의 신규 염 | |
WO2022065823A1 (ko) | 4-메톡시-2-펜에틸이소인돌린-1-온 유도체 및 이를 포함하는 신경질환의 치료용 조성물 | |
WO2018105816A1 (ko) | 통증 억제용 조성물 | |
WO2010150984A2 (ko) | 안정성이 향상된 무정형 아데포비어 디피복실 고체분산체 및 이의 제조방법 | |
WO2023277331A1 (ko) | Dyrk1 억제제인 피롤로[3,2-c]피리딘 유도체 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10859932 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12013501054 Country of ref document: PH |
|
ENP | Entry into the national phase |
Ref document number: 2013540871 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13989407 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10859932 Country of ref document: EP Kind code of ref document: A1 |